RIPK1 and cancer: Ponatinib has been used as template to design new inhibitors with improved selectivity for RIPK1.54 The B-RafV600E inhibitors Vemurafenib and Dabrafenib inhibit RIPK3, with Dabrafenib being effective in the submicromolar range.55 Dabrafenib competes with ATP for binding to RIPK3 and alleviates acetaminophen-induced liver injury.55 Here, we demonstrate that the anti-cancer agent Sorafenib acts as an inducer of cell death at high concentration but as an inhibitor of RIPK-dependent cell death at lower concentration.